QUEBEC CITY, March 11 /CNW/ - Medicago Inc. (TSX-V : MDG - News; the "Company"), today announced that Mr. Andy Sheldon, President and CEO, will be presenting at the Partnering for Global Health Forum 2008 in Washington, DC, today at 3:30 p.m. EST. Mr. Sheldon will give an overview of the Company's development of vaccines and manufacturing technologies, and recent preclinical results of its H5N1 Avian Influenza lead vaccine candidate generated from plant-made Virus-Like Particles.

ADVERTISEMENT

Partnering for Global Health Forum 2008 is an international partnering meeting focused on accelerating the development of medicines for neglected diseases of the developing world. Leaders from the biopharmaceutical industry, potential funders and international health experts will discuss the pressing needs for innovation and explore new avenues for progress and potential partnerships. The forum is organized by BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO), and sponsored by the Bill & Melinda Gates Foundation.

About Medicago Inc.

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market.

Additional information about Medicago is available at www.medicago.com.

Forward-Looking Statements

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

	    The TSX Venture Exchange assumes no responsibility for the content or 	    accuracy of this press release